Brief: Ionis Pharmaceuticals Inc - Announces Positive Results From Phase 3 Studies Of Olezarsen - SEC Filing
02/09/2025 13:40
Ionis Pharmaceuticals Inc IONS.O: IONIS PHARMACEUTICALS INC - ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDIES OF OLEZARSEN - SEC FILING IONIS PHARMACEUTICALS INC - CORE AND CORE2 STUDIES MET PRIMARY ENDPOINT WITH OLEZARSEN - SEC FILING IONIS PHARMACEUTICALS INC - OLEZARSEN SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE - SEC FILING IONIS PHARMACEUTICALS INC - PLANS SNDA SUBMISSION TO FDA BY YEAR-END - SEC FILING IONIS PHARMACEUTICALS INC: OLEZARSEN MET SECONDARY ENDPOINT OF REDUCTION IN ACUTE PANCREATITIS EVENTS Source text: [ID:n0001140361-25-033541] Further company coverage: IONS.O
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors